NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + DS-1594 Sensitive: C2 – Inclusion Criteria venetoclax + DS-1594 Sensitive : C2	venetoclax + DS-1594 Sensitive: C2 – Inclusion Criteria venetoclax + DS-1594 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
NPM1 mutation	Chronic Myelomonocytic Leukemia	NPM1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
NPM1 mutation	Myelodysplastic Syndrome	NPM1 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3
NPM1 mutation	Myelodysplastic Syndrome	NPM1 mutation	Myelodysplastic Syndrome	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	JNJ-6617 Sensitive: C3 – Early Trials JNJ-6617 Sensitive : C3	JNJ-6617 Sensitive: C3 – Early Trials JNJ-6617 Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D

NPM1 mutation

Associations